Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer

This study has been completed.
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00627666
First received: February 29, 2008
Last updated: March 25, 2013
Last verified: July 2009